1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Musculoskeletal conditions
  5. Arthritis

Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs

Technology appraisal guidance [TA768] Published: 02 February 2022

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 144 KB 02 February 2022  

Final draft guidance

  • Final draft guidance  
  • Final appraisal document PDF 262 KB 06 January 2022  
  • Committee papers PDF 4.2 MB 06 January 2022  
  • Public committee slides PDF 1004 KB 06 January 2022  

Invitation to participate

  • Final stakeholder list PDF 167 KB 07 October 2020  
  • NICE's response to comments on the draft scope and provisional stakeholder list PDF 414 KB 07 October 2020  
  • Final scope PDF 195 KB 07 October 2020  
  • Equality impact assessment (Scoping) PDF 127 KB 07 October 2020  

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators  
  • Draft scope pre referral PDF 213 KB 12 June 2020  
  • Draft matrix pre referral PDF 167 KB 12 June 2020